Department of Neurosurgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
BMC Neurol. 2020 Nov 26;20(1):429. doi: 10.1186/s12883-020-02003-9.
Detecting and treating neuropsychological deficits after aneurysmatic subarachnoid hemorrhage (aSAH) play a key role in regaining independence; however, detecting deficits relevant to social and professional reintegration has been difficult and optimal timing of assessments remains unclear. Therefore, we evaluated the feasibility of administering the Neuropsychological Assessment Battery screening module (NAB-S) to patients with aSAH, assessed its value in predicting the ability to return to work and characterized clinical as well as neuropsychological recovery over the period of 24 months.
A total of 104 consecutive patients treated for aSAH were recruited. After acute treatment, follow up visits were conducted at 3, 12 and 24 months after the hemorrhage. NAB-S, Montreal Cognitive Assessment (MoCA) and physical examination were performed at each follow up visit.
The NAB-S could be administered to 64.9, 75.9 and 88.9% of the patients at 3, 12 and 24 months, respectively. Moderate impairment of two or more neuropsychological domains (e.g speech, executive function, etc.) significantly correlated with inability to return to work at 12 and 24 months as well as poor outcome assessed by the extended Glasgow Outcome Scale (GOSE) at 3, 12 and 24 months. The number of patients with favorable outcomes significantly increased from 25.5% at discharge to 56.5 and 57.1% at 3 and 12 months, respectively, and further increased to 74.1% after 24 months.
The NAB-S can be administered to the majority of patients with aSAH and can effectively detect clinically relevant neuropsychological deficits. Clinical recovery after aSAH continues for at least 24 months after the hemorrhage which should be considered in the design of future clinical trials.
检测和治疗蛛网膜下腔出血(aSAH)后的神经认知缺陷在恢复独立性方面起着关键作用;然而,检测与社会和职业重新融合相关的缺陷一直具有挑战性,评估的最佳时机仍不清楚。因此,我们评估了对 aSAH 患者进行神经心理评估电池筛查模块(NAB-S)测试的可行性,评估其预测重返工作能力的价值,并描述了 24 个月内的临床和神经认知恢复情况。
共纳入 104 例连续接受 aSAH 治疗的患者。急性治疗后,在出血后 3、12 和 24 个月进行随访。每次随访时进行 NAB-S、蒙特利尔认知评估(MoCA)和体格检查。
NAB-S 可分别在 3、12 和 24 个月时对 64.9%、75.9%和 88.9%的患者进行评估。两个或更多神经认知领域(如言语、执行功能等)的中度损害与 12 和 24 个月时无法重返工作岗位以及 3、12 和 24 个月时扩展格拉斯哥结局量表(GOSE)的不良结局显著相关。出院时预后良好的患者比例从 25.5%显著增加至 3 个月时的 56.5%和 12 个月时的 57.1%,在 24 个月后进一步增加至 74.1%。
NAB-S 可用于大多数 aSAH 患者,能够有效检测到具有临床意义的神经认知缺陷。aSAH 后的临床恢复至少在出血后 24 个月持续,这在未来临床试验的设计中应加以考虑。